Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia

T-cell–engaging immunotherapies are exciting new approaches to treat patients with acute lymphoblastic leukemia (ALL). These unique agents, which include blinatumomab, a CD3/CD19 bispecific antibody, and chimeric antigen receptor (CAR) modified T cells targeted to CD19 have shown unprecedented remis...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Hematology Am Soc Hematol Educ Program
Main Authors: Frey, Noelle V., Porter, David L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2016
Teme:
Optimizing Treatments for High-Risk Acute Lymphoblastic Leukemia: What It Takes to Move the Needle
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142489/
https://ncbi.nlm.nih.gov/pubmed/27913530
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki